PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
Phathom Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$7.01+0.09 (+1.30%)
Close on Oct 19, 2026
- Market cap
- $587.07M
- P/E (TTM)
- –
- Dividend yield
- –
Phathom Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 82.9%
- Operating margin
- -17.0%
- Net margin
- -41.3%
- Return on equity, FY2025
- 64.0%
Financial strength
- Current ratio
- 1.92
- Debt to equity
- -0.48
- Debt to assets
- 50.3%
- Cash to current liabilities
- 118.7%
Valuation
- P/E ratio
- –
- Price to sales
- 2.45
- Price to book
- –
- Dividend yield
- –